At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Fatima Cardoso, MD, from Champalimaud Cancer Centre, Lisbon, Portugal, discusses the implementation of ESMO guidelines on the treatment of metastatic HER2-positive breast cancer in a case study presentation, including the use of the antibody-drug conjugate, T-DM1, and the anti-HER2 antibody, pertuzumab, in different settings of treatment.
ESMO Clinical Practice Guidelines: Breast cancer case presentation
5th February 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?